Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    18166547 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17
Condition: Attention Deficit Disorder With Hyperactivity
Interventions: Drug: SPD503 (Guanfacine hydrochloride) (2 mg);   Drug: SPD503 (3 mg);   Drug: SPD503 (4 mg);   Drug: Placebo

Indicates status has not been verified in more than two years